In the wake of the Food & Drug Administration’s (FDA) ambitious unified agenda, on July 13, 2026, the agency published a proposed rule aiming to align its regulatory frameworks with “how distributed manufacturing actually works.” The proposed rule would create a tailored drug establishment registration framework for certain distributed manufacturing establishments (DMEs) and clarify the registration and listing obligations applicable to certain foreign drug establishments.
Read Article
#DSCSAGuidance